Health and Healthcare

Wednesday's Top Biotech and Medical Stocks

From BioHealth Investor

Biotechnology

SGX PHARMACEUTICALS [SGXP] +25.78%
HALOZYME THERAPEUTIC [HTI] +11.59%
FAVRILLE, INC. [FVRL] +10.41%
INVITROGEN CORP [IVGN] +9.92%
ARIAD PHARM INC [ARIA] +6.36%

Diagnostic Substances

ABAXIS INC [ABAX] +6.84%
PRESSURE BIOSCIENC [PBIO] +5.27%
AMER BIO MEDICA [ABMC] +4.76%
IMMUNOMEDICS INC [IMMU] +4.30%
MONOGRAM BIOSCIENCES [MGRM] +3.70%

Drug Delivery

DELCATH SYSTEMS INC [DCTH] +4.92%
NOVADEL PHARMA INC [NVD] +4.14%
FLAMEL TECH SA ADR [FLML] +2.59%
ELAN CP PLC ADR [ELN] +1.27%
INSITE VISION INC [ISV] +1.23%

Drug Manufacturers

LANNETT COMPANY INC [LCI] +4.21%
ARQULE INC [ARQL] +3.96%
SINOVAC BIOTECH LTD [SVA] +3.95%
MARSHALL EDWARDS [MSHL] +3.88%
NITROMED, INC. [NTMD] +3.46%

Medical Appliances & Equipment

BSD MEDICAL CORP [BSM] +12.16%
DIGIRAD CORPORATION [DRAD] +6.16%
ARRHYTHMIA RES TECH [HRT] +5.31%
CRYOLIFE INC [CRY] +5.25%
UROLOGIX INC [ULGX] +5.20%

Medical Instruments & Supplies

BIOTEL INC [BTEL.OB] +13.14%
CAS MEDICAL SYS INC [CASM] +7.33%
STEN CORPORATION [STEN] +4.63%
MESA LABS INC [MLAB] +4.41%
OCULUS INNOVATIVE SC [OCLS] +3.64%

Medical Laboratories & Research

NEOGENOMICS INC [NGNM.OB] +4.76%
MEDTOX SCIENTFIC INC [MTOX] +3.91%
GENOMIC HEALTH, INC. [GHDX] +3.52%
MEDASORB TECHNOLOGS [MSBT.OB] +2.86%
PSYCHEMEDICS NEW [PMD] +1.30%

http://www.biohealthinvestor.com/

Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.